Pharmacogeriatrics and the Kidney

  • Paula Scibona
  • Waldo H. Belloso


Older people constitute a particular group regarding pharmacotherapeutics for many reasons. They are high consumers of prescription drugs (up to 30% of all commonly prescribed medications); the age-related pharmacokinetic and pharmacodynamic changes and high rate of comorbidities put them at an increased risk of drug interactions, adverse effects, and inadequate dosing. In this chapter we are going to describe how physiology changes secondary to aging can predispose elderly people to suffer from pharmacological adverse effects and their impact over the pharmacology of drugs may help to optimize drug use and to avoid complications in this age group.


Aged Pharmacokinetics Pharmacodynamics Renal aging Drug interactions Therapeutics Drug monitoring Pharmacogenomics 


  1. 1.
    Waltman KWS. Preventing adverse drug reactions. Philadelphia: Hanley & Belfus; 2000.Google Scholar
  2. 2.
    Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.CrossRefGoogle Scholar
  3. 3.
    Weiss BD, Lee JK. Aging: is your patient taking too many pills? J Fam Pract. 2012;61(11):652–61.PubMedGoogle Scholar
  4. 4.
    Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003;78(12):1564–77.CrossRefGoogle Scholar
  5. 5.
    Willlams CM. Using medications appropriately in older adults. Am Fam Physician. 2002;66(10):1917–24.PubMedGoogle Scholar
  6. 6.
    Musso CG. Geriatric nephrology and the “nephrogeriatric giants”. Int Urol Nephrol. 2002;34:255–6.CrossRefGoogle Scholar
  7. 7.
    Musso CG. Acute renal failure in the elderly: pearls for its assessment and treatment. Electron J Biomed. 2005;1:1–93.Google Scholar
  8. 8.
    Renkke H, Denker B. Renal pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2007.Google Scholar
  9. 9.
    Onuigbo MA, Onuigbo NT. The Syndrome of Rapid Onset End-Stage Renal Disease (SOROESRD) – a new Mayo Clinic Dialysis services experience, January 2010–February 2011. In: Di Iorio B, Heidland A, Onuigbo M, Ronco C, editors. Hemodialysis: when, how, why, vol. 2012. New York: NOVA Publishers; 2012. p. 443–85.Google Scholar
  10. 10.
    Onuigbo M, Onuigbo N, Musso CG. Syndrome of rapid-onset end-stage renal disease in incident Mayo Clinic chronic hemodialysis patients. Indian J Nephrol. 2014;24:75–81.CrossRefGoogle Scholar
  11. 11.
    Musso CG, Jauregui J. Renin-angiotensin-aldosterone system and the aging kidney. Endocrinol Metab. 2014;9(6):1–4.Google Scholar
  12. 12.
    Musso CG, Oreopoulos D. Renal changes in the elderly. In: Katlic M, editor. Cardiothoracic surgery in the elderly. Evidence-based practice. New York: Springer; 2011.Google Scholar
  13. 13.
    Musso CG, Macias Nunez JF, Oreopoulos DG. Physiological similarities and differences between renal aging and chronic renal disease. J Nephrol. 2007;20(5):586–7.PubMedGoogle Scholar
  14. 14.
    Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiol. 2011;119(Suppl 1):1–5.CrossRefGoogle Scholar
  15. 15.
    Hojs R, Bevc S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharmacol Res. 2004;24(2–3):49–54.PubMedGoogle Scholar
  16. 16.
    Törner A, Odar-Cederlöf I, Kallner A, Akner G. Renal function in community-dwelling frail elderly. Comparison between measured and predicted glomerular filtration rate in the elderly and proposal for a new cystatin C-based prediction equation. Aging Clin Exp Res. 2008;20(3):216–25.CrossRefGoogle Scholar
  17. 17.
    Wei L, Ye X, Pei X, Wu J, Zhao W. Reference intervals for serum cystatin C and factors influencing cystatin C levels other than renal function in theelderly. PLoS One. 2014;9(1):e86066.CrossRefGoogle Scholar
  18. 18.
    Keller F. Kidney function and age. Nephrol Dial Transplant. 1987;2(5):382.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int. 2007;72(5):632–7.CrossRefGoogle Scholar
  20. 20.
    Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010;5(2):314–27.CrossRefGoogle Scholar
  21. 21.
    Musso CG, Oreopoulos D. Geriatric nephrology. In: Pathy J, Sinclair A, Morley J, editors. Principles and practice of geriatric medicine. West Sussex: Wiley; 2012.Google Scholar
  22. 22.
    Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, Schuchardt M, Tölle M, Ziebig R, van der Giet M, Martus P. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157(7):471–8.CrossRefGoogle Scholar
  23. 23.
    Alshaer IM, Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, Farmer CK, Irving J, O’Riordan SE, Dalton RN, Lamb EJ. External validation of the Berlin equations for estimation of GFR in the elderly. Am J Kidney Dis. 2014;63(5):862–5.CrossRefGoogle Scholar
  24. 24.
    Denneboom W, Dautzenberg MG, Grol R, De Smet PA. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract. 2006;56(528):504–10.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Scibona P, Angriman F, Vazquez C, Ferreyro BL, Perelsztein AG, Simonovich VA, Jauregui JR, Musso CG, Belloso WH. Individualisation of drug therapy in older people. Rev Clin Gerontol. 2014;24:145–57.CrossRefGoogle Scholar
  26. 26.
    Musso CG, Michelángelo H, Vilas M, Reynaldi J, Martinez B, Algranati L, Macías Núñez JF. Creatinine reabsorption by the aged kidney. Int Urol Nephrol. 2009;41(3):727–31.CrossRefGoogle Scholar
  27. 27.
    Musso CG, Ghezzi L, Ferraris J. Renal physiology in newborns and old people: similar characteristics but different mechanisms. Int Urol Nephrol. 2004;36(2):273–6.CrossRefGoogle Scholar
  28. 28.
    Musso CG, Macías-Núñez JF. Dysfunction of the thick loop of Henle and senescence: from molecular biology to clinical geriatrics. Int Urol Nephrol. 2011;43:249–52.CrossRefGoogle Scholar
  29. 29.
    Musso CG, Rd M, Algranati L, Farias Edos R. Renal potassium excretion: comparison between chronic renal disease patients and old people. Int Urol Nephrol. 2005;37(1):167–70.CrossRefGoogle Scholar
  30. 30.
    Musso C, Liakopoulos DMR, Imperiali N, Algranati L. Transtubular potassium concentration gradient: comparison between healthy old people and chronic renal failure patients. Int Urol Nephrol. 2006;38(2):387–90.CrossRefGoogle Scholar
  31. 31.
    Lacy C, Armstrong L, Goldman M, Lance L. Drug information handbook. Philadelphia: Lexi-Comp; 2004. p. 646–8.Google Scholar
  32. 32.
    Musso CG, Juarez R, Vilas M, Navarro M, Rivera H, Jauregui R. Renal calcium, phosphorus, magnesium and uric acid handling: comparison between stage III- chronic kidney disease and healthy oldest old. Int Urol Nephrol. 2012;44(5):1559–62.CrossRefGoogle Scholar
  33. 33.
    Musso CG, Alvarez Gregory J, Macías Núñez JF. Renal handling of uric acid, magnesium, phosphorus, calcium, and acid base in the elderly. In: Núñez M, Cameron S, Oreopoulos D, editors. Renal ageing: health and disease. New York: Springer; 2008. p. 155–71.Google Scholar
  34. 34.
    Musso CG. Magnesium metabolism in health and disease. Int Urol Nephrol. 2009;41:357–62.CrossRefGoogle Scholar
  35. 35.
    Musso CG, Reynaldi J, Vilas M, De Miguel R, Imperiali N, Algranati L. Fractional excretion of K, Na and Cl following furosemide infusion in healthy, young and very old people. Int Urol Nephrol. 2010;42(1):273–7.CrossRefGoogle Scholar
  36. 36.
    Musso CG, Macías Núñez JF. Renal handling of water and electrolytes in the old and old-old healthy aged. In: Núñez M, Cameron S, Oreopoulos D, editors. Renal ageing: health and disease. New York: Springer; 2008. p. 141–54.Google Scholar
  37. 37.
    Fulop T Jr, Worum I, Csongor J, Foris G, Leovey A. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology. 1985;31(1):6–14.CrossRefGoogle Scholar
  38. 38.
    Ginsberg G, Hattis D, Russ A, Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect. 2005;113(9):1243–9.CrossRefGoogle Scholar
  39. 39.
    McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163–84.CrossRefGoogle Scholar
  40. 40.
    Perucca E. Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol. 2007;81:183–99.CrossRefGoogle Scholar
  41. 41.
    Noreddin AM, Haynes V. Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. Drugs Aging. 2007;24(4):275–92.CrossRefGoogle Scholar
  42. 42.
    Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47(5):297–321.CrossRefGoogle Scholar
  43. 43.
    Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185–91.CrossRefGoogle Scholar
  44. 44.
    Wang L. Changes in pharmacokinetics in the elderly and therapeutic drug monitoring of antiarrhythmic drugs. Life Sci J. 2007;4:1–7.Google Scholar
  45. 45.
    Dettli L. Drug dosage in renal disease. Clin Pharmacokinet. 1976;1(2):126–34.CrossRefGoogle Scholar
  46. 46.
    Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521–90.CrossRefGoogle Scholar
  47. 47.
    Ruiz JG, Array S, Lowenthal DT. Therapeutic drug monitoring in the elderly. Am J Ther. 1996;3(12):839–60.CrossRefGoogle Scholar
  48. 48.
    Ghiculescu R. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr. 2008;31(2):42–4.CrossRefGoogle Scholar
  49. 49.
    Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.CrossRefGoogle Scholar
  50. 50.
    Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (part II). Clin Pharmacokinet. 1991;21(4):262–73.CrossRefGoogle Scholar
  51. 51.
    Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101(5):354–9.CrossRefGoogle Scholar
  52. 52.
    Bonetti A, Franceschi T, Apostoli P, Cetto GL, Recaldin E, Molino A, et al. Cisplatin pharmacokinetics in elderly patients. Ther Drug Monit. 1994;16(5):477–82.CrossRefGoogle Scholar
  53. 53.
    Greenblatt DJ, Abernethy DR, Shader RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit. 1986;8(3):249–55.CrossRefGoogle Scholar
  54. 54.
    Waade RB, Molden E, Refsum H, Hermann M. Serum concentrations of antidepressants in the elderly. Ther Drug Monit. 2012;34(1):25–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Paula Scibona
    • 1
  • Waldo H. Belloso
    • 1
  1. 1.Clinical Pharmacology Section, Internal Medicine ServiceHospital Italiano de Buenos AiresBuenos AiresArgentina

Personalised recommendations